Stereoselective pharmacokinetics of flurbiprofen in humans and rats

doi:10.1002/jps.2600770805

Journal of Pharmaceutical Sciences

Volume 77, Issue 8, August 1988, Pages 666-669

https://doi.org/10.1002/jps.2600770805 Get rights and content

Abstract

Flurbiprofen, a 2-arylpropionic acid (2-APA) nonsteroidal anti-inflammatory drug (NSAID), exists as racemate and is used as such. Although the activity of 2-APAs is due mainly to their S-enantiomers, information on the pharmacokinetics of flurbiprofen is usually based on the measurement of total concentrations of S- and R-flurbiprofen. In this work, the pharmacokinetics of flurbiprofen enantiomers following single doses were studied in humans and rats. Upon iv administration of 10 mg/kg of racemic flurbiprofen to male Sprague-Dawley rats, the plasma concentrations were consistently higher for S-flurbiprofen than for R-flurbiprofen (AUC = 134 ± 39 versus 41 ± 9 mg-L⁻¹ h). In bile duct-cannulated rats, the biliary excretion contained only 3.6-5.2% of the dose as conjugated flurbiprofen (S:R = 1.2–2.1). After administration of R-flurbiprofen to the rat, both enantiomers were found in plasma [AUC(R ):AUC(S ) = 0.10-0.16], indicating a limited extent of enantiomeric bioinversion. This is consistent with the previously reported limited extent of flurbiprofen uptake into fat. In healthy volunteers also, significant stereoselectivity was observed in the plasma concentration of the drug after 100-mg oral racemic doses [AUC-(S):AUC(R) = 45.4 ± 12.7:40.1 ± 14.3 mg-L⁻¹ h]. As compared with the R-enantiomer, S-flurbiprofen has a smaller volume of distribution (7.23 ± 1.9 versus 8.41 ± 3.0 L) and total clearance (1.23 ± 0.34 versus 1.47 ± 0.50 L/h), but an equal half-life (4.21 ± 1.2 versus 4.18 ± 1.3 h). In urine, on the other hand, the R-configuration was predominant, as greater amounts of the R-enantiomer were found both as conjugated flurbiprofen and as an unidentified metabolite. Negligible amounts of intact flurbiprofen enantiomers were detected in urine. The observed stereoselectivity in humans cannot be attributed to enantiomeric bioinversion, as S-flurbiprofen was not detected in plasma and urine after oral administration of R-flurbiprofen.

References and Notes (29)

KaiserD.G. et al.
J. Pharm. Sci.
(1976)
RubinA. et al.
J. Pharm. Sci.
(1985)
SinghN.N. et al.
J. Pharm. Sci.
(1986)
FosterR.T. et al.
J. Pharm. Sci.
(1988)
FosterR.T. et al.
J. Pharm. Sci.
(1988)
KemmererJ. et al.
J. Pharm. Sci.
(1979)
UptonR.A. et al.
J. Pharm. Sci.
(1980)
JamaliF. et al.
J. Pharm. Sci.
(1985)
FearsR. et al.
J. Lipid Res.
(1978)
WilliamsK. et al.
Biochem. Pharmacol.
(1986)

BruneK.

Agents Actions

(1985)

DayR.O. et al.

Br. J. Clin. Pharmacol.

(1987)

HuttA.J. et al.

Clin. Pharmacokinet.

(1984)

AdamsS.S. et al.

J. Pharm. Pharmacol.

(1976)

Cited by (115)

Pharmacology of Analgesics
2023, Anesthesia and Analgesia in Laboratory Animals
Pain management for laboratory animals is critical to assure the welfare of the animals and to minimize the confounding effects of pain on research results. There are three main types of pain: nociceptive pain, inflammatory pain and pathologic pain. Nociceptive and inflammatory pain provide a protective role. Nociceptive pain is a high-threshold pain used to sense noxious stimuli to prevent tissue damage. Inflammatory pain is initiated by the immune response to tissue damage. Pathologic pain results from abnormal nervous system responses or disease state. This chapter reviews the physiological mechanism of pain, the analgesic mechanism of action, pharmacology, clinical application and adverse effects of five main groups of analgesic drugs used in pain management: (1) nonsteroidal anti-inflammatory drugs (NSAIDs), (2) opioids, (3) α₂-adrenergic agonists, (4) NMDA-receptor antagonists, and (5) gabapentanoids.
Correlation between glucuronidation and covalent adducts formation with proteins of nonsteroidal anti-inflammatory drugs
2018, European Journal of Pharmaceutical Sciences
Citation Excerpt :
Furthermore, as the potency of glucuronidation varies with the NSAID (Magdalou et al., 1990), glucuronidation properties can affect subsequent covalent bond formation. Although most NSAIDs, particularly 2-arylpropanoic acids, are used as a racemate in clinical practice, stereoselective pharmacokinetics (Foster and Jamali, 1988; Iwaki et al., 1995; Jamali et al., 1988), glucuronidation (Ikuta et al., 2017; Chakir et al., 1994; Mano et al., 2007), protein binding (Bischer et al., 1995b), and mitochondrial toxicity (Browne et al., 1999) have been reported in enantiomers of NSAIDs. These results indicate that development of NSAIDs-induced liver injury can depend on stereoselective character of NSAIDs.
Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause idiosyncratic liver injury. Mechanisms involved in NSAID-induced liver injury are complex. Previous studies have suggested that acyl glucuronide of NSAIDs (NSAIDs-Glu) plays an important role in the development of liver injury via covalently binds to proteins and the resultant adduct induces immunological toxicity. As only some NSAIDs-Glu are commercially available, the evaluation of covalent protein adduct formation using ready-made NSAIDs-Glu is difficult and inconvenient. Moreover, glucuronidation potency varies with the NSAID, including stereoisomers. Therefore, in this study, we simultaneously examined the glucuronidation and covalent adduct formation using enantiomers of parent NSAIDs (ibuprofen, naproxen, pranoprofen, ketoprofen, and flurbiprofen) in rat liver microsomes. Glucuronides and covalent adducts were quantified by HPLC. The amount of covalent adduct increased with NSAIDs-Glu formation in the rat liver microsomes in a time-dependent manner. A significant positive correlation was observed between the AUC of NSAIDs-Glu and that of covalent adduct, except ketoprofen. Although ketoprofen exhibited the highest glucuronidation rate among the NSAIDs investigated, the amount of covalent adduct was similar to that for pranoprofen, which had the lowest glucuronidation rate. Thus, it may be difficult for ketoprofen glucuronide to covalently bind with proteins in the rat liver microsomes. Our results suggested that the amount of glucuronide formed is a key factor in predicting covalent bond formation with protein in NSAIDs, in addition to degradability and bindability with proteins of NSAIDs-Glu. Further studies are required to confirm the relationship between the tendency of glucuronidation and the formation of covalent adducts of NSAIDs.
Flurbiprofen
2012, Profiles of Drug Substances, Excipients and Related Methodology
Citation Excerpt :
Between 65% and 85% of flurbiprofen and its metabolites are present as glucuronide and sulfate conjugates. Stereoselective HPLC of human plasma has also been performed [137]. After oral administration of 25 mg of the R(−)-enantiomer of flurbiprofen, no indication was found that inversion to the S(+)-enantiomer occurred.
Racemic flurbiprofen is one of the well-known forms of nonsteroidal anti-inflammatory drug (NSAID) substances. The enantiopure (S)-enantiomer exhibits a stronger anti-inflammatory activity (30-fold higher as compared to rac-flurbiprofen); however, flurbiprofen is still currently produced in large quantities as a racemic mixture. rac-Flurbiprofen is a NSAID used in the treatment of pain or inflammation in humans. Flurbiprofen is indicated for the management of vernal keratoconjunctivitis, postoperative ocular inflammation, herpetic stromal keratitis, excimer laser photorefractive keratectomy, and ocular gingivitis. Recent reports suggest potential topical and systemic use of flurbiprofen in radioprotection, the inhibition of colon tumor, the protection of postirradiation myelosuppression, pain management after foot surgery, and peridontal surgery. It is recognized that the enantiomers of biologically active compounds usually display different physiological activities. There has also been very rapid progress in asymmetric synthetic methods in recent years. As a result, increasing attention is being paid to the synthesis of nonracemic chiral drugs. One of the major groups of anti-inflammatory agents is the arylpropanoic acid, such as flurbiprofen, where the activity resides in the (S) isomers.
Flurbiprofen
2007, xPharm: The Comprehensive Pharmacology Reference
General Issues of Chirality in Pharmacology
2022, Progress in Drug Research
A sensitive UPLC-MS/MS method for the determination of flurbiprofen in rat plasma: Application to real sample
2021, Journal of Chromatographic Science

View all citing articles on Scopus

View full text

ArticlesStereoselective pharmacokinetics of flurbiprofen in humans and rats

Abstract

J. Pharm. Sci.

J. Pharm. Sci.

J. Pharm. Sci.

J. Pharm. Sci.

J. Pharm. Sci.

J. Pharm. Sci.

J. Pharm. Sci.

J. Pharm. Sci.

J. Lipid Res.

Biochem. Pharmacol.

Agents Actions

Br. J. Clin. Pharmacol.

Clin. Pharmacokinet.

J. Pharm. Pharmacol.

Articles
Stereoselective pharmacokinetics of flurbiprofen in humans and rats